MNPR News & Events

Monopar Therapeutics announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 showing greater neurologic benefit versus standard of care in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology, AAN, Annual Meeting 2026, taking place April 18-22, 2026. In a late-breaker oral and poster presentation titled "Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial," Dr. Peter Hedera, MD, PhD, Department of Neurology, University of Louisville School of Medicine, will present results showing that ALXN1840 provided greater neurologic improvement and significantly less worsening than standard of care through Week 48, with durable neurologic benefit observed over multiple years of treatment.

Monopar Therapeutics (MNPR) announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. She most recently served as COO of Avadel Pharmaceuticals (AVDL).